MRK Jan 2025 100.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:55PM EST. Market open.
| Previous close | 18.10 |
| Open | 17.01 |
| Bid | 15.50 |
| Ask | 17.45 |
| Strike | 100.00 |
| Expiry date | 2025-01-17 |
| Day's range | 17.01 - 17.01 |
| Contract range | N/A |
| Volume | |
| Open interest | 553 |
- Reuters
Merck sees sharp decline in COVID sales for 2023 after strong fourth quarter
Merck & Co on Thursday forecast 2023 earnings below Wall Street estimates along with an expected steep decline in sales of its COVID-19 antiviral treatment, and its shares fell around 2%. The U.S. drugmaker did report a higher-than-expected fourth-quarter profit on strong sales of the COVID pill molnupiravir in Asia and its blockbuster cancer drug Keytruda. Merck forecast 2023 adjusted earnings of $6.80 to $6.95 per share, lower than analysts' average estimate of $7.36.
- Business Wire
Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
RAHWAY, N.J., February 02, 2023--Merck Announces Fourth-Quarter and Full-Year 2022 Financial Results
- Zacks
Will Keytruda & Gardasil Aid Merck (MRK) Sales in Q4 Earnings?
Merck's (MRK) key products like cancer drug Keytruda and HPV vaccine Gardasil are expected to have driven sales in Q4.
© 2023 Yahoo. All rights reserved.
